<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="13369">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02932878</url>
  </required_header>
  <id_info>
    <org_study_id>DSXS 1503a</org_study_id>
    <nct_id>NCT02932878</nct_id>
  </id_info>
  <brief_title>An Open Label, Safety Study to Assess the Potential for Adrenal Suppression</brief_title>
  <official_title>An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS Topical Product in Patients With Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taro Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taro Pharmaceuticals USA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An Open Label, Safety Study to Assess the Potential for Adrenal Suppression Following
      Treatment with DSXS (Taro Pharmaceuticals U.S.A., Inc.) in Patients with Plaque Psoriasis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the potential of DSXS to suppress HPA axis function in patients with mild to
      moderate plaque psoriasis.

      To evaluate the efficacy parameters and adverse event (AE) profile of DSXS administered to
      patients with mild to moderate plaque psoriasis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2, 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients in the study with HPA axis suppression</measure>
    <time_frame>28 Days</time_frame>
    <description>Hypothalamic Pituitary Adrenal (HPA) Axis Response to Cosyntropin</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>DSXS topical</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>administered twice daily for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DSXS topical</intervention_name>
    <description>topical treatment</description>
    <arm_group_label>DSXS topical</arm_group_label>
    <other_name>active</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or non pregnant, non lactating females

        Exclusion Criteria:

          -  Patients under 2 years of age
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Natalie Yantovskiy</last_name>
    <role>Study Director</role>
    <affiliation>Taro Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Natalie Yantovskiy</last_name>
    <phone>914-345-9001</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Natalie Yantovskiy</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Taro Pharmaceuticals USA Inc.</name>
      <address>
        <city>Hawthorne</city>
        <state>New York</state>
        <zip>10532</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalie Yantovskiy</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 16, 2017</lastchanged_date>
  <firstreceived_date>October 12, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
